DKK340.90
0.64% today
Copenhagen, Aug 13, 04:53 pm CET
ISIN
DK0060257814
Symbol
ZEAL

Zealand Pharma Target price 2025 - Analyst rating & recommendation

Zealand Pharma Classifications & Recommendation:

Buy
83%
Hold
17%

Zealand Pharma Price Target

Target Price DKK867.00
Price DKK343.10
Potential
Number of Estimates 18
18 Analysts have issued a price target Zealand Pharma 2026 . The average Zealand Pharma target price is DKK867.00. This is higher than the current stock price. The highest price target is
DKK1,176.00 242.76%
register free of charge
, the lowest is
DKK404.00 17.75%
register free of charge
.
A rating was issued by 24 analysts: 20 Analysts recommend Zealand Pharma to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Zealand Pharma stock has an average upside potential 2026 of . Most analysts recommend the Zealand Pharma stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million DKK 62.69 9,653.00
81.71% 15,297.99%
EBITDA Margin -1,978.78% 5.86%
1,172.79% 100.30%
Net Margin -1,720.90% 4.92%
738.24% 100.29%

17 Analysts have issued a sales forecast Zealand Pharma 2025 . The average Zealand Pharma sales estimate is

DKK9.7b
Unlock
. This is
17,233.45% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
DKK10.6b 18,975.24%
Unlock
, the lowest is
DKK8.8b 15,635.32%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 DKK62.7m 81.71%
2025
DKK9.7b 15,297.99%
Unlock
2026
DKK5.5b 43.11%
Unlock
2027
DKK3.7b 33.34%
Unlock
2028
DKK2.5b 30.40%
Unlock
2029
DKK4.5b 76.14%
Unlock
2030
DKK4.1b 9.31%
Unlock
2031
DKK7.3b 78.16%
Unlock
2032
DKK11.8b 63.36%
Unlock

13 Analysts have issued an Zealand Pharma EBITDA forecast 2025. The average Zealand Pharma EBITDA estimate is

DKK566m
Unlock
. This is
141.08% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
DKK7.9b 671.61%
Unlock
, the lowest is
DKK-2.1b 54.98%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 DKK-1.2b 132.77%
2025
DKK566m 145.59%
Unlock
2026
DKK-43.4m 107.68%
Unlock
2027
DKK184m 523.65%
Unlock
2028
DKK985m 435.62%
Unlock
2029
DKK2.0b 106.78%
Unlock

EBITDA Margin

2024 -1,978.78% 1,172.79%
2025
5.86% 100.30%
Unlock
2026
-0.79% 113.48%
Unlock
2027
5.02% 735.44%
Unlock
2028
38.66% 670.12%
Unlock
2029
45.39% 17.41%
Unlock

16 Zealand Pharma Analysts have issued a net profit forecast 2025. The average Zealand Pharma net profit estimate is

DKK475m
Unlock
. This is
140.03% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
DKK6.5b 644.51%
Unlock
, the lowest is
DKK-2.0b 71.80%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 DKK-1.1b 53.30%
2025
DKK475m 143.99%
Unlock
2026
DKK-468m 198.53%
Unlock
2027
DKK-948m 102.78%
Unlock
2028
DKK-330m 65.16%
Unlock
2029
DKK-154m 53.33%
Unlock

Net Margin

2024 -1,720.90% 738.24%
2025
4.92% 100.29%
Unlock
2026
-8.51% 272.97%
Unlock
2027
-25.90% 204.35%
Unlock
2028
-12.96% 49.96%
Unlock
2029
-3.43% 73.53%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share DKK -16.24 6.71
30.55% 141.32%
P/E 51.11
EV/Sales 1.93

16 Analysts have issued a Zealand Pharma forecast for earnings per share. The average Zealand Pharma EPS is

DKK6.71
Unlock
. This is
139.96% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
DKK91.32 643.90%
Unlock
, the lowest is
DKK-28.81 71.59%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 DKK-16.24 30.55%
2025
DKK6.71 141.32%
Unlock
2026
DKK-6.61 198.51%
Unlock
2027
DKK-13.41 102.87%
Unlock
2028
DKK-4.67 65.18%
Unlock
2029
DKK-2.18 53.32%
Unlock

P/E ratio

Current -20.43 73.93%
2025
51.11 350.11%
Unlock
2026
-51.87 201.49%
Unlock
2027
-25.58 50.68%
Unlock
2028
-73.43 187.06%
Unlock
2029
-157.33 114.26%
Unlock

Based on analysts' sales estimates for 2025, the Zealand Pharma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 335.14 125.81%
2025
1.93 99.42%
Unlock
2026
3.40 75.76%
Unlock
2027
5.10 50.01%
Unlock
2028
7.33 43.68%
Unlock
2029
4.16 43.23%
Unlock
2030
4.59 10.27%
Unlock
2031
2.57 43.87%
Unlock
2032
1.58 38.78%
Unlock

P/S ratio

Current 481.48 180.53%
2025
2.78 99.42%
Unlock
2026
4.88 75.76%
Unlock
2027
7.32 50.01%
Unlock
2028
10.52 43.68%
Unlock
2029
5.97 43.23%
Unlock
2030
6.59 10.27%
Unlock
2031
3.70 43.87%
Unlock
2032
2.26 38.79%
Unlock

Current Zealand Pharma Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Jul 14 2025
CANTOR FITZGERALD
Locked
Locked
Locked Jun 23 2025
BTIG
Locked
Locked
Locked Jun 23 2025
WILLIAM BLAIR & COMPANY
Locked
Locked
Locked Jun 22 2025
JEFFERIES
Locked
Locked
Locked Jun 21 2025
KBC SECURITIES
Locked
Locked
Locked Jun 19 2025
DNB CARNEGIE
Locked
Locked
Locked May 08 2025
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Jul 14 2025
Locked
CANTOR FITZGERALD:
Locked
Locked
Jun 23 2025
Locked
BTIG:
Locked
Locked
Jun 23 2025
Locked
WILLIAM BLAIR & COMPANY:
Locked
Locked
Jun 22 2025
Locked
JEFFERIES:
Locked
Locked
Jun 21 2025
Locked
KBC SECURITIES:
Locked
Locked
Jun 19 2025
Locked
DNB CARNEGIE:
Locked
Locked
May 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today